NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

膀胱鏡市場:2021年∼至2026年的預測

Cystoscope Market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1023198
出版日期 內容資訊 英文 111 Pages
商品交期: 最快1-2個工作天內
價格
膀胱鏡市場:2021年∼至2026年的預測 Cystoscope Market - Forecasts from 2021 to 2026
出版日期: 2021年07月08日內容資訊: 英文 111 Pages
簡介

全球膀胱鏡子的市場規模,在預測期間內預計以4.43%的年複合成長率成長,從2019年的5億8463萬6000美元到2026年達到7億9179萬1000美元的市場規模。

所謂膀胱鏡,是一種用於執行膀胱鏡檢查(也稱為膀胱尿道鏡檢查)的輕型微型相機連接儀器,允許醫生檢查和治療下泌尿道(尿道、前列腺、膀胱頸和膀胱)。全球膀胱鏡市場的成長可能歸因於全球尿路疾病患病率的上升。亞太地區佔有主要佔有率。

本報告提供全球膀胱鏡子市場調查,市場概要,市場成長要素及阻礙因素分析,市場機會,各類型,各地區的市場規模的變化與預測,競爭情形,並提供主要企業簡介等資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 假設

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 新加入業者的威脅
    • 替代品的威脅
    • 產業的競爭企業間的敵對關係
  • 產業的價值鏈分析

第5章 各類型的膀胱鏡市場分析

  • 簡介
  • 硬式膀胱鏡子
  • 軟性膀胱鏡子

第6章 各應用領域的膀胱鏡市場分析

  • 簡介
  • 泌尿科
  • 婦產科

第7章 各終端用戶的膀胱鏡市場分析

  • 簡介
  • 醫院
  • 門診病人手術中心

第8章 各地區的膀胱鏡市場分析

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 法國
    • 德國
    • 義大利
    • 其他
  • 中東和非洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 泰國
    • 台灣
    • 印尼
    • 其他

第9章 競爭環境與分析

  • 主要的參與者與策略分析
  • 新興參與者和市場收益性
  • 合併,收購,協定,及合作
  • 供應商競爭力矩陣

第10章 企業簡介

  • Stryker
  • PENTAX Medical
  • Olympus Medical Corporation
  • Richard Wolf GmbH
  • Karl Storz
  • NeoScope Inc.
  • Coloplast Group
  • Cogentix Medical
  • Henke-Sass Wolf
  • Advanced Health Care Resources
目錄
Product Code: KSI061611601

The global cystoscope market is expected to grow at a compound annual growth rate of 4.43% over the forecast period to reach a market size of US$791.791 million in 2026 from US$584.636 million in 2019. A cystoscope is a thin, telescope-like tube with a light and tiny camera attached instrument used to perform a cystoscopy, also known as cystourethroscopy, that allows a physician to examine and treat the lower urinary tract (urethra, prostate, bladder neck, and bladder). The cystoscope is inserted into the bladder through the urethra for the evaluation, treatment, or diagnoses of the conditions such as Bladder cancer, haematuria, frequent urinary tract infections (UTIs), Urinary blockage, Urinary stones, etc. making cystoscopy procedures one of the most commonly performed procedures in the urology office settings. Major companies have been providing novel and advanced solutions for their customers. For instance, Ambu, one of the largest suppliers of innovative and advanced single-use endoscopes, would be providing solutions for urology, in the coming years. The company had announced that it would launch a novel single-use, sterile, and high-resolution cystoscope in the year 2022. The company have also stated that they would launch a novel and single-use digital flexible ureteroscope in the year 2022. These trends and developments are expected to play a major role in the market growth, during the forecast period.

Rising incidences of urinary tract diseases boost the market.

The growth in the global cystoscope market may be attributed to the rising prevalence of urinary tract diseases globally. As per the data by the National Kidney Foundation, there are approximately 10 million doctor visits for urinary tract infections in the US. Similar rising incidences of other diseases such as prostate cancer, stones, bladder cancer, etc. will also boost the market during the given time frame. As per Cancer Research UK, prostate cancer is the most common cancer in men with around 47,700 new prostate cancer cases in the UK every year. However, complications such as infections, bleeding, and swollen urethra that may arise during cystoscopy procedures might restrain the growth of the market during the forecast period. According to a journal published in the United States National Library of Medicine National Institutes of Health, urinary tract infections are one of the most common infections, with an average lifetime incidence of 50-60% in most adult women. Urinary tract infections are some of the most common infections in the United States. The prevalence in women over 65 years is around 20%, compared with around 11% of the overall population. Moreover, there are around 258,000 cases of pyelonephritis in the United States, per year, with a higher and bigger frequency among females. In women, who are aged between 18-49 years, the total approximate incidence of pyelonephritis is around 28/10,000. These trends are expected to accelerate the demand for novel cystoscope devices and applications, in the coming years.

Asia Pacific to have a major share.

The market is expected to surge in the region due to the rising cases of urinary infections and prostate cancer. In India, according to the Indian Council of Medical Research, the incidence rate of prostate cancer in the country had been around 9-10/100,000 population, which is comparatively higher as compared to countries in Asia and Africa. In China, according to the National Cancer Registration Institute, prostate cancer has been the most common tumor in the male urinary system since the year 2008. These trends are expected to accelerate the demand for novel and advanced cystoscope products and systems.

Latest Developments.

  • In May 2021, UroViu Corporation, one of the major developers of a suite of self-contained, portable, and versatile single-use cystoscopy solutions, had announced that they had received a clearance from the United States of Food and Drug Administration to market and launch its third device, known as Uro-G. The novel product had been a single-use cystoscope with a detectable tip that allows physicians to perform diagnostic and interventional urologic procedures in their clinics, at any time, and in any room. This development is expected to have a positive impact on the market, in the coming years.
  • In May 2021, KARL STORZ Endoscopy America Inc., one of the key players in the market, announced the launch of its novel PDD Blue Light Flexible Video Cystoscopy System for improved detection of non-muscle invasive bladder cancer. The company had stated that the novel indications would surge the treatment of innovative therapy, across the United States.
  • In April 2021, Ambu Inc., one of the key players in the market, announced that it had received Health Canada clearance for the aScope 4 Crysto, the firm's major advanced and innovative flexible cystoscope platform for urology. The novel product would allow urologists in Canada immediate access to a single-use cystoscope option for managing, treating, and diagnosing lower urinary disorders, such as bladder cancer, incontinence, and hematuria.

Market Segmentation:

  • By Type
  • Rigid Cystoscope
  • Flexible Cystoscope
  • By Applications
  • Urology
  • Gynecology
  • By End-User
  • Hospitals
  • Ambulatory Surgical Centers
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Thailand
  • Taiwan
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Cystoscope Market Analysis, By Type

  • 5.1. Introduction
  • 5.2. Rigid Cystoscope
  • 5.3. Flexible Cystoscope

6. Cystoscope Market Analysis, By Applications

  • 6.1. Introduction
  • 6.2. Urology
  • 6.3. Gynecology

7. Cystoscope Market Analysis, By End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Ambulatory Surgical Centers

8. Cystoscope Market Analysis, By Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. France
    • 8.4.3. Germany
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Thailand
    • 8.6.5. Taiwan
    • 8.6.6. Indonesia
    • 8.6.7. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles

  • 10.1. Stryker
  • 10.2. PENTAX Medical
  • 10.3. Olympus Medical Corporation
  • 10.4. Richard Wolf GmbH
  • 10.5. Karl Storz
  • 10.6. NeoScope Inc.
  • 10.7. Coloplast Group
  • 10.8. Cogentix Medical
  • 10.9. Henke-Sass Wolf
  • 10.10. Advanced Health Care Resources